Literature DB >> 28586220

Discovery of Allosteric Inhibitors Targeting the Spliceosomal RNA Helicase Brr2.

Misa Iwatani-Yoshihara, Masahiro Ito, Michael G Klein1, Takeshi Yamamoto, Kazuko Yonemori, Toshio Tanaka, Masanori Miwa, Daisuke Morishita, Satoshi Endo, Richard Tjhen1, Ling Qin1, Atsushi Nakanishi, Hironobu Maezaki, Tomohiro Kawamoto.   

Abstract

Brr2 is an RNA helicase belonging to the Ski2-like subfamily and an essential component of spliceosome. Brr2 catalyzes an ATP-dependent unwinding of the U4/U6 RNA duplex, which is a critical step for spliceosomal activation. An HTS campaign using an RNA-dependent ATPase assay and initial SAR study identified two different Brr2 inhibitors, 3 and 12. Cocrystal structures revealed 3 binds to an unexpected allosteric site between the C-terminal and the N-terminal helicase cassettes, while 12 binds an RNA-binding site inside the N-terminal cassette. Selectivity profiling indicated the allosteric inhibitor 3 is more Brr2-selective than the RNA site binder 12. Chemical optimization of 3 using SBDD culminated in the discovery of the potent and selective Brr2 inhibitor 9 with helicase inhibitory activity. Our findings demonstrate an effective strategy to explore selective inhibitors for helicases, and 9 could be a promising starting point for exploring molecular probes to elucidate biological functions and the therapeutic relevance of Brr2.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28586220     DOI: 10.1021/acs.jmedchem.7b00461

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Therapeutic approaches to treat human spliceosomal diseases.

Authors:  Anthony B DeNicola; Yi Tang
Journal:  Curr Opin Biotechnol       Date:  2019-02-15       Impact factor: 9.740

Review 2.  Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.

Authors:  Maxime Blijlevens; Jing Li; Victor W van Beusechem
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

Review 3.  Roles and mechanisms of alternative splicing in cancer - implications for care.

Authors:  Sophie C Bonnal; Irene López-Oreja; Juan Valcárcel
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

Review 4.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

Review 5.  Targeting mRNA processing as an anticancer strategy.

Authors:  Joana Desterro; Pedro Bak-Gordon; Maria Carmo-Fonseca
Journal:  Nat Rev Drug Discov       Date:  2019-09-25       Impact factor: 84.694

Review 6.  Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.

Authors:  Jung-Chun Lin
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

7.  Chemical genetic inhibition of DEAD-box proteins using covalent complementarity.

Authors:  Krister J Barkovich; Megan K Moore; Qi Hu; Kevan M Shokat
Journal:  Nucleic Acids Res       Date:  2018-09-28       Impact factor: 16.971

Review 8.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Michela Sebastiano; Veronica Zelli; Stefano Guadagni; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2020-06-15

Review 9.  Genetic Drivers of Head and Neck Squamous Cell Carcinoma: Aberrant Splicing Events, Mutational Burden, HPV Infection and Future Targets.

Authors:  Zodwa Dlamini; Mohammed Alaouna; Sikhumbuzo Mbatha; Ahmed Bhayat; Mzubanzi Mabongo; Aristotelis Chatziioannou; Rodney Hull
Journal:  Genes (Basel)       Date:  2021-03-15       Impact factor: 4.096

Review 10.  Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma.

Authors:  I Gede Putu Supadmanaba; Giulia Mantini; Ornella Randazzo; Mjriam Capula; Ittai B Muller; Stella Cascioferro; Patrizia Diana; Godefridus J Peters; Elisa Giovannetti
Journal:  Epigenetics       Date:  2021-05-30       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.